var data={"title":"Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7167?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information&quot;</a> and <a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50067790\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Yellow Fever Vaccine Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Sanofi Pasteur has announced that YF-Vax yellow fever vaccine will be unavailable from mid-2017 to mid-2018 due to delays in the production process. The FDA has approved the importation of Sanofi Pasteur&rsquo;s Stamaril under an investigational new drug program. Stamaril is comparable in safety and efficacy to YF-Vax, but is not licensed in the US and can only be provided to a limited number of clinics. For more information, contact Sanofi Pasteur at 1-800-822-2463.</p>\n        <p style=\"text-indent:0em;\">Further information can be found at <a target=\"_blank\" href=\"https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access&amp;token=sa7YK+LBunsSwIfkUh5jbNo/DzCyDlytn2uwsJ0M7zNov12g5fJSQy6ubu65ctA9uIGf3pWvv0dkoV1rbnRS0eBTFyShh4gIlBx8xixUyCA=&amp;TOPIC_ID=13021\" target=\"_blank\">https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235039\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>YF-VAX</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235040\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>YF-VAX</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042673\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Live (Viral)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042696\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Yellow fever prevention (immunization):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization </i>(CDC/ACIP [Staples 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 months to &lt;9 months: Limited data available: SubQ: 0.5 mL as a single dose &ge;10 days before travel</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;9 months, Children, and Adolescents: SubQ: 0.5 mL as a single dose &ge;10 days before travel</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster:</i> Based on currently available data, the World Health Organization (WHO) and CDC/ACIP have determined that vaccine failure is rare and booster doses are generally not needed. A single dose of the vaccine is adequate for most travelers. The World Health Assembly removed the 10-year booster dose requirement from the International Health Regulations in July 2016 (WHO 2016). However, additional dose(s) are recommended for certain patient populations with conditions at the time of their initial dose that may limit immune response (pregnant women, hematopoietic stem cell transplant recipients, HIV patients). A booster dose may also be given (&ge;10 years after last dose) to those who may be at high risk for yellow fever disease (eg, certain laboratory workers [depending on antibody titers] and travelers to endemic locations for prolonged periods) (CDC/ACIP [Staples 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Yellow fever prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization: </i>SubQ: 0.5 mL as a single dose &ge;10 days before travel</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster:</i> Based on currently available data, the World Health Organization (WHO) and CDC/ACIP have determined that vaccine failure is rare and booster doses are generally not needed. A single dose of the vaccine is adequate for most travelers. The World Health Assembly removed the 10-year booster dose requirement from the International Health Regulations in July 2016 (WHO 2016). However, additional dose(s) are recommended for certain patient populations with conditions at the time of their initial dose that may limit immune response (pregnant women, hematopoietic stem cell transplant recipients, HIV patients). A booster dose may also be given (&ge;10 years after last dose) to those who may be at high risk for yellow fever disease (eg, certain laboratory workers [depending on antibody titers] and travelers to endemic locations for prolonged periods) (CDC/ACIP [Staples 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51193564\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51193565\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235042\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Yellow fever prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Primary immunization:</i> SubQ: One dose (0.5 mL) &ge;10 days before travel</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster:</b> Based on currently available data, the World Health Organization (WHO) and CDC/ACIP have determined that vaccine failure is rare and booster doses are generally not needed. A single dose of the vaccine is adequate for most travelers. The World Health Assembly removed the 10-year booster dose requirement from the International Health Regulations in July 2016 (WHO 2016). However, booster dose(s) are recommended for certain patient populations with conditions at the time of their initial dose that may limit immune response (eg, pregnant women, hematopoietic stem cell transplant recipients, HIV patients). A booster dose may also be given (&ge;10 years after last dose) to those who may be at increased risk for yellow fever disease (eg, certain laboratory workers [depending on antibody titers] and travelers to endemic locations for prolonged periods) (CDC/ACIP [Staples 2015]; WHO 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990945\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988275\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235021\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [17D-204 strain]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stamaril: &ge;1000 units per 0.5 mL dose [produced in chicken embryos; packaged with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">YF-VAX: &ge;4.74 log<sub>10</sub> plaque-forming units (PFU) per 0.5 mL dose [single-dose or 5-dose vial; produced in chicken embryos; contains gelatin; packaged with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235009\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50067019\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Stamaril: FDA Investigational New Drug application approved April 2017. Refer to the CDC for current, detailed recommendations on availability and appropriate use. <a target=\"_blank\" href=\"https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access&amp;token=sa7YK+LBunsSwIfkUh5jbNo/DzCyDlytn2uwsJ0M7zNov12g5fJSQy6ubu65ctA9uIGf3pWvv0dkoV1rbnRS0eBTFyShh4gIlBx8xixUyCA=&amp;TOPIC_ID=13021\" target=\"_blank\">https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50509237\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, yellow fever vaccine is distributed only through approved vaccinating centers, including travel clinics and some health departments. These designated centers are listed in a registry at the CDC travel website: <a target=\"_blank\" href=\"https://wwwnc.cdc.gov/travel/yellow-fever-vaccination-clinics/search&amp;token=kthqUQ1y8hnG9tdeSgsvsFgNZ6tnrYPWwzw5EPyJ874udy4CunangDS6CMLCwLk0bgFZljfaT+FiMRlb3xybZTU3rSMxMn6/BbPXteu2Ch4=&amp;TOPIC_ID=13021\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellow-fever-vaccination-clinics/search</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734163\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the CDC-approved Vaccine Information Statement (VIS) is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/yf.html&amp;token=/BDNNu50rGFlRmPwZGhnaxtHcWNMFfvzjkI4V1Mqcw3idVl85qeR70euHfPsvb4tH04GVKNOM/wIekIIacmwHg==&amp;TOPIC_ID=13021\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/yf.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042700\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: SubQ: Use within 60 minutes following reconstitution; keep suspension refrigerated until used. Swirl well before withdrawing dose; avoid vigorous shaking to prevent foaming of suspension. Administer by SubQ injection into the anterolateral aspect of the thigh or arm; not for intradermal, IV, or IM administration. If inadvertently administered IM, the dose does not need to be repeated. Use of expired vaccine is not considered a valid dose and should be repeated after 28 days. For booster doses, if the date of previous vaccination cannot be determined and the patient requires vaccination, the booster dose can be given (CDC/ACIP [Staples 2010]). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235036\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Vaccine must be used within 60 minutes of reconstitution. Keep suspension refrigerated until used (CDC/ACIP [Staples 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042674\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Active immunization against yellow fever virus for individuals who are either traveling to or living in endemic yellow fever areas and for laboratory workers who may be exposed to the virus (FDA approved in ages &ge;9 months and adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The  Advisory Committee on Immunization Practices (ACIP) recommends vaccination for: Persons traveling to or living in areas at risk for yellow fever transmission; persons traveling to countries which require vaccination for international travel; laboratory personnel who may be exposed to the yellow fever virus or concentrated preparations of the vaccine (CDC/ACIP [Staples 2015]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although the vaccine is approved for use in infants &ge;9 months of age, the CDC recommends use in infants as young as 6 months under unusual circumstances (eg, travel to an area where exposure is unavoidable) (CDC/ACIP [Staples 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235055\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site, localized edema (at injection site), pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute disseminated encephalomyelitis, anaphylaxis, brain disease, cranial nerve palsy (bulbar), Guillain-Barr&eacute; syndrome, hypersensitivity at injection site, hypersensitivity reaction (immediate; including asthma, dyspnea, bronchospasm, pharyngeal edema), residual mass at injection site, urticaria, vaccine-associated neurotropic disease (rare), vaccine-associated viscerotropic disease (rare; may be associated with multi-organ failure)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235027\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute hypersensitivity to egg or chick embryo protein, or any component of the formulation, including gelatin; infants &lt;9 months (per manufacturer); infants &lt;6 months (CDC/ACIP 2010 guidelines); severely immunosuppressed patients (eg HIV infection, leukemia, lymphoma, thymic disease, generalized malignancy, or immunosuppression due to drugs or radiation); lactating women providing breast-milk to infants &lt;9 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to latex (natural rubber)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235012\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]). Use is contraindicated in patients with immediate-type hypersensitivity reactions to eggs. Less severe or localized manifestations of allergy are not contraindications; in general, persons who are able to eat eggs or egg products may receive the vaccine. A hypersensitivity screening test and desensitization procedure is available for persons with suspected or known severe egg sensitivity. Consult manufacturer's labeling for details.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccine-associated neurotropic disease (YEL-AND): Isolated cases of post-vaccine encephalitis (some fatal) have been reported within 30 days after administration. Risk factors include age &lt;9 months, age &gt;60 years, and immunodeficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccine-associated viscerotropic disease (YEL-AVD): Has been reported following first dose of vaccine; may present as non-specific multi-organ system failure or symptoms similar to fulminant wild-type yellow fever virus (including potentially fatal hepatic failure and internal bleeding). Age &gt;60 years is a risk factor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Use is contraindicated in patients with severe or febrile illness; vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Patients who are immunosuppressed have a theoretical risk of encephalitis with yellow fever vaccine administration; consider delaying travel or obtaining a waiver letter. Patients on low-dose or short-term corticosteroids are not considered immunosuppressed and may be offered the vaccine. If vaccination is only to satisfy an international requirement (as opposed to decreasing risk of infection), efforts should be made to obtain a waiver letter. Per the ACIP guidelines, use is contraindicated in patients with symptomatic HIV infection or patients with CD4+ counts &lt;200/mm<sup>3</sup> (or &lt;15% of total lymphocytes in children &lt;6 years); use caution when administering the vaccine to patients with asymptomatic infection with CD4+ counts 200 to 499/mm<sup>3</sup> (or 15% to 24% of total lymphocytes in children &lt;6 years) (CDC/ACIP [Staples 2010]). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines (ACIP [Kroger 2017]; IDSA [Rubin 2014]). Live vaccines should be administered &ge;4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy. Specific recommendations for use of this vaccine in immunocompromised patients considering international travel as well as contacts of immunocompromised patients are available from the IDSA (ACIP [Kroger 2017; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Due to an increased incidence of serious adverse events observed in older adults compared to younger adults, use with caution in the elderly &ge;60 years, particularly in patients who have not previously received the vaccine. The risk for vaccine-associated neurologic disease (YEL-AND) and vaccine-associated viscerotropic disease (YEL-AVD) is also increased. The ACIP guidelines note that if travel is unavoidable, the decision to vaccinate travelers &ge;60 years should be made after weighing the risks vs benefits (CDC/ACIP [Staples 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: The manufacturer contraindicates use in infants &lt;9 months of age due to risk of encephalitis. The CDC allows for use in infants 6-8 months of age when possible exposure with the yellow fever virus is unavoidable and the risk of infection exists (CDC/ACIP [Staples 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gelatin: Product may contain gelatin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood donation: Transfusion-related transmission of yellow fever vaccine virus has been reported; wait 2 weeks after immunization with yellow fever vaccine to donate blood (CDC/ACIP [Staples 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malnutrition: Malnourished persons may have a decreased response to vaccination (CDC/ACIP [Staples 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819280\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use in infants &lt;6 months (&lt;9 months per manufacturer) is contraindicated due to an increased risk for encephalitis. A higher incidence of encephalitis was also observed in infants who received the yellow fever vaccine between 6 to 9 months of age; reported incidence variable: historic (prior to vaccine age restrictions) estimations were 50 to 400 cases per 100,000 and within  VAERS (ages &gt;9 months), the reported rate is 0.4 to 0.8 per 100,000.  The ACIP guidelines allow for use in this age group (6 to 9 months) if risks of exposure are determined to be greater than the risk of adverse vaccine effects.  Travel to rural areas in yellow fever endemic zones or to countries with epidemics should be postponed or avoided in this age group, whenever possible (CDC/ACIP [Staples 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300231\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235015\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13021&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fotemustine: May enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk for vaccine-related disease may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235030\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Avoid use in pregnant women unless travel to high-risk areas is unavoidable. Pregnant women may not produce an adequate immune response to the vaccine, particularly in the third trimester (CDC/ACIP [Staples 2015]). Adverse events were not observed in the mother or fetus following vaccination during the third trimester of pregnancy in Nigerian women (n=101, including 89 in their third trimester); however, maternal seroconversion was reduced (39% seroconversion at 2 to 4 weeks after administration) (Nasidi 1993). Inadvertent exposure early in the first trimester of pregnancy (n=480, mean gestational age 5.7 &plusmn; 4.9 weeks) in Brazilian women did not show decreased maternal seroconversion (98.2% seropositive at &ge;6 weeks after administration); no increased risk for major congenital abnormalities was observed (Suzano 2006). Cord blood from an infant whose mother was vaccinated during the first trimester tested positive for IgM antibodies (indicating congenital infection); no adverse events were noted in the infant (Tsai 1993). Vaccine should be administered if travel to an endemic area is unavoidable and the infant should be monitored after birth. Tests to verify maternal immune response may be considered (CDC/ACIP [Staples 2010]). If a pregnant woman is to be vaccinated only to satisfy an international requirement (as opposed to decreasing risk of infection), efforts should be made to obtain a waiver letter. Women should wait 4 weeks after receiving vaccine before conceiving (CDC/ACIP [Staples 2010]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to variable seroconversion during pregnancy, women who were initially vaccinated while pregnant may need a booster dose prior to traveling again to an area at risk for yellow fever virus infection (CDC/ACIP [Staples 2015].</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042702\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29243485\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Yellow fever vaccine is a live vaccine that offers active immunization against yellow fever infection at an effective immune response rate of nearly 100% of patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235026\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Seroconversion: 10 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &ge;30 years (possibly life-long protection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1042705\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Some countries require a valid International Certification of Vaccination or Prophylaxis (ICVP) showing receipt of vaccine. Certificate is valid beginning 10 days following vaccination (booster doses received within 10 years are valid from the date of vaccination). The WHO previously required revaccination every 10 years to maintain traveler's vaccination certificate; however, due to evidence of long term efficacy, this revaccination requirement was removed in July 2016. Certificates valid at the time of the change will automatically remain valid for the life of the traveler; do not modify, erase, or change the document as these alterations may render it invalid (WHO 2016). Current requirements and recommendations for immunization related to travel destination can be obtained from the CDC Travelers' Health Web site (www.cdc.gov/travel). All travelers to endemic areas should be advised of the risks of yellow fever disease and all available methods to prevent it. All travelers should take protective measures to avoid mosquito bites.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Desensitization may be used in individuals with a history of severe egg sensitivity if immunization is imperative and the individual has a positive skin test to the vaccine.  Necessary emergency equipment should be immediately available and desensitization should only be performed by a health care provider experienced in the management of anaphylaxis. The following successive doses should be administered subcutaneously at 15- to 20-minute intervals:</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">&bull; 0.05 mL of 1:10 dilution</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; 0.05 mL of full strength</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; 0.1 mL of full strength</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; 0.15 mL of full strength</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; 0.2 mL of full strength</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The following CDC agencies may be contacted if serologic testing is needed or for advice when administering yellow fever vaccine to pregnant women, infants &lt;9 months, or patients with altered immune status:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Division of Vector-Borne Infectious Diseases: 970-221-6400</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Division of Global Migration and Quarantine: 404-498-1600</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038857\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arilvax (NL, ZA);</li>\n      <li>Stamaril (AE, AR, AT, AU, BE, BG, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GT, HK, HN, HR, ID, IE, IL, IN, IS, IT, KR, LK, LT, LU, LV, MT, MY, NI, NO, NZ, PA, PE, PK, PL, PT, PY, RO, SE, SG, SI, SK, SV, TR, UY, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Transfusion-related transmission of yellow fever vaccine virus &minus; California, 2009. <i>MMWR Morb Mortal Wkly Rep</i>. 2010;59(2):34-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/20094025/pubmed\" target=\"_blank\" id=\"20094025\">20094025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010;59(RR-7):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/20671663 /pubmed\" target=\"_blank\" id=\"20671663 \">20671663 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed on April 28, 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/21617632/pubmed\" target=\"_blank\" id=\"21617632\">21617632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. <i>Trans R Soc Trop Med Hyg</i>. 1993; 87: 337-339.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/8236412 /pubmed\" target=\"_blank\" id=\"8236412 \">8236412 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNeil MM, Hibbs BF, Miller ER, Cano MV. Notes from the Field: Errors in Administration of an Excess Dosage of Yellow Fever Vaccine - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2018;67(3):109-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/29370153/pubmed\" target=\"_blank\" id=\"29370153\">29370153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009; 374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(23):647-650.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/26086636 /pubmed\" target=\"_blank\" id=\"26086636 \">26086636 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Staples JE, Gershman M, Fischer M, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010; 59(RR-7):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/20671663/pubmed\" target=\"_blank\" id=\"20671663\">20671663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suzano CE, Amaral E, Sato HK, et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Campinas Group on Yellow Fever Immunization during Pregnancy. <i>Vaccine</i>. 2006; 24(9):1421-1426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/16236402/pubmed\" target=\"_blank\" id=\"16236402\">16236402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. <i>J Infect Dis</i>. 1993;168(6):1520-1523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/8245539 /pubmed\" target=\"_blank\" id=\"8245539 \">8245539 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). International travel and health: new yellow fever vaccination requirements for travelers, July 27, 2016. Geneva, Switzerland: World Health Organization; 2016. Available at http://www.who.int/ith/updates/20160727/en/.8245539 </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). International travel and health: world&ndash; yellow fever vaccination booster, June 5, 2014. Geneva, Switzerland: World Health Organization; 2014. Available at http://www.who.int/ith/updates/20140605/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Meeting of the Strategic Advisory Group of Experts on Immunization, April 2013 &ndash; conclusions and recommendations. <i>Wkly Epidemiol Rec</i>. 2013;88(20):201-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/23696983/pubmed\" target=\"_blank\" id=\"23696983\">23696983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    YF-VAX (yellow fever vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; June 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13021 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50067790\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F235039\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F235040\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1042673\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1042696\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51193564\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51193565\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F235042\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990945\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988275\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F235021\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F235009\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50067019\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50509237\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734163\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1042700\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F235036\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1042674\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F235055\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F235027\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F235012\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819280\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300231\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F235015\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F235030\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1042702\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F29243485\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F235026\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1042705\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038857\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13021|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</a></li><li><a href=\"topic.htm?path=yellow-fever-vaccine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Yellow fever vaccine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}